Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.32 |
| ▸ | HTR3A | P46098 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7836101 | 1.00 | ALDH1A1 (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Vosaroxin SCHEMBL674441 | 0.90 | HTR3A (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Vosaroxin SCHEMBL195037 | 0.90 | HTR3A (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Vosaroxin SCHEMBL15933161 | 0.90 | HTR3A (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Vosaroxin SCHEMBL3207291 | 0.90 | HTR3A (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Vosaroxin SCHEMBL7824869 | 0.89 | HTR3A (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Vosaroxin SCHEMBL7824853 | 0.89 | HTR3A (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Vosaroxin SCHEMBL7824841 | 0.89 | HTR3A (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Vosaroxin SCHEMBL18694851 | 0.89 | HTR3A (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 | |
| Vosaroxin SCHEMBL29914037 | 0.89 | HTR3A (0.35) | ALDH1A1PPARGMAPK10KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931339-B1 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS INC (US) | 2018-05-16 | — | — | EP | claimed |
| EP-2214662-B1 | (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION WITH GEMCITABINE FOR USE IN TREATING CANCER | SUNESIS PHARMACEUTICALS INC (US) | 2016-07-13 | — | — | EP | claimed |
| EP-2049109-B1 | COMBINED USE OF (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID AND CYTARABINE (ARA-C) FOR THE TREATMENT OF LEUKEMIA | SUNESIS PHARMACEUTICALS INC (US) | 2015-11-18 | — | — | EP | claimed |
| EP-1725233-B1 | PHARMACEUTICAL COMPOSITION COMPRISING SNS-595 AND USES THEREOF | SUNESIS PHARMACEUTICALS INC (US) | 2011-01-05 | — | — | EP | claimed |
| EP-1931339-B1 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS INC (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3284745-A1 | COMPOSITION OF (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | Sunesis Pharmaceuticals, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2382214-B1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-3141250-A1 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY | Sunesis Pharmaceuticals, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2214662-B1 | (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION WITH GEMCITABINE FOR USE IN TREATING CANCER | SUNESIS PHARMACEUTICALS INC (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2049109-B1 | COMBINED USE OF (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID AND CYTARABINE (ARA-C) FOR THE TREATMENT OF LEUKEMIA | SUNESIS PHARMACEUTICALS INC (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-2249831-A2 | METHODS OF USING (+)-1,4-DIHYDRO-7-Ý(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL¨-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS | Sunesis Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-2214662-A1 | METHODS OF USING (+)-1,4-DIHYDRO-7-Ý(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL¨-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY | Sunesis Pharmaceuticals, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-2049109-A2 | COMBINED USE OF (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID AND CYTARABINE (ARA-C) FOR THE TREATMENT OF LEUKEMIA | Sunesis Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1931339-A1 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF CANCER | Sunesis Pharmaceuticals, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |